December 18, 2013 | Israeli stem cell company Pluristem Therapeutics is moving forward with the agreement reached with Korean company CHA Bio & Diostech signed last June. The two companies have agreed on a strategic partnership which will also include a $10.4 million mutual investment via share swap.
Related posts
Clean Energy Company That Mimics The Sun Raises $22M
February 02, 2023
Blood Test Offers Hope For Lung Cancer Patients
February 02, 2023
Israel Opens Its First Satellite Observatory
February 02, 2023
Cloud Data-Securing Startup Raises $30M
February 01, 2023
Facebook comments